Postneoadjuvant treatment for triple-negative breast cancer

Area of Science:

• Oncology
• Clinical Trials
• Breast Cancer Research

Background:

• Triple-negative breast cancer (TNBC) presents a poor prognosis due to limited treatment options.
• Pathological complete response (pCR) is a key prognostic factor for patients receiving neoadjuvant therapy.
• There is a significant unmet need for effective postneoadjuvant treatments in high-risk TNBC patients.

Purpose of the Study:

• To map the landscape of clinical trials in the postneoadjuvant setting for TNBC.
• To identify distinct patterns in clinical trial design for postneoadjuvant therapies.
• To review risk-adapted treatment strategies aimed at improving outcomes for high-risk TNBC patients.

Main Methods:

• Review of clinical trials focusing on the postneoadjuvant space for TNBC.
• Categorization of trial designs into three distinct patterns based on risk stratification.
• Analysis of treatment intensification strategies informed by baseline, surgical, or postsurgical factors.

Main Results:

• Three main patterns of clinical trial design in the postneoadjuvant setting were identified.
• Type 2 approaches, utilizing residual disease characteristics, have been most common (e.g., capecitabine, Olaparib).
• Type 1 (baseline factors, e.g., pembrolizumab) and Type 3 (postsurgical factors, e.g., ctDNA) approaches are also being investigated.

Conclusions:

• Postneoadjuvant risk-adapted treatments are vital for improving survival in high-risk TNBC patients.
• Clinical trial designs are evolving to better tailor adjuvant therapy intensification.
• Further investigation into Type 3 approaches is ongoing to validate their clinical utility.